Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
作者： Gloria Karen Cheal , Warren Chew , Mahmoud Mirmehrabi , Mannching Sherry Ku , Qinhong Lu
DOI:
关键词: Chemistry 、 Stereochemistry 、 Butenamide 、 Medicinal chemistry 、 Epidermal Growth Factor Receptor Family 、 Alkoxy group 、 Salt (chemistry)
摘要: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods preparing crystalline forms, the associated compounds, and pharmaceutical compositions containing same. salts are useful in treating cancers, particularly those affected by kinases epidermal growth factor receptor family.
lens.org参考文章(501)
Hua Yang, William Kong, Lili He, Jian-Jun Zhao, Joshua D. O'Donnell, Jiawang Wang, Robert M. Wenham, Domenico Coppola, Patricia A. Kruk, Santo V. Nicosia, Jin Q. Cheng, MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research. ,vol. 68, pp. 425- 433 ,(2008) , 10.1158/0008-5472.CAN-07-2488
J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, S.D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Journal of Clinical Oncology. ,vol. 20, pp. 4292- 4302 ,(2002) , 10.1200/JCO.2002.03.100
Lee Martin Greenberger, Yixian Zhang, Tammy Michelle Sadler, Philip Frost, Method of treating estrogen receptor positive carcinoma ,(2001)
Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller, Ronald B. Natale, Vincent Miller, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Ira Oliff, James A. Reeves, Michael K. Wolf, Annetta D. Krebs, Steven D. Averbuch, Judith S. Ochs, John Grous, Abderrahim Fandi, David H. Johnson, Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Journal of Clinical Oncology. ,vol. 22, pp. 785- 794 ,(2004) , 10.1200/JCO.2004.07.215
Alberto Ocaña, Eitan Amir, None, Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions Cancer Treatment Reviews. ,vol. 35, pp. 685- 691 ,(2009) , 10.1016/J.CTRV.2009.08.001
Christopher D. Coldren, Barbara A. Helfrich, Samir E. Witta, Michio Sugita, Razvan Lapadat, Chan Zeng, Anna Barón, Wilbur A. Franklin, Fred R. Hirsch, Mark W. Geraci, Paul A. Bunn, Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines Molecular Cancer Research. ,vol. 4, pp. 521- 528 ,(2006) , 10.1158/1541-7786.MCR-06-0095
Jeffrey A. Meyerhardt, Andrew X. Zhu, Peter C. Enzinger, David P. Ryan, Jeffrey W. Clark, Matthew H. Kulke, Craig C. Earle, Michele Vincitore, Ann Michelini, Susan Sheehan, Charles S. Fuchs, Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer Journal of Clinical Oncology. ,vol. 24, pp. 1892- 1897 ,(2004) , 10.1200/JCO.2005.05.3728
Daniel J. Freeman, Robert Radinsky, Todd Juan, Epidermal growth factor receptor mutations ,(2006)
Thomas E. Davis, Paul P. Carbone, Drug Treatment of Breast Cancer Drugs. ,vol. 16, pp. 441- 464 ,(1978) , 10.2165/00003495-197816050-00004
April Scott, Ravi Salgia, Biomarkers in lung cancer: from early detection to novel therapeutics and decision making Biomarkers in Medicine. ,vol. 2, pp. 577- 586 ,(2008) , 10.2217/17520363.2.6.577